Comment from Anonymous

Dear FDA Docket Management Staff, Integrated Framework for RT-MSCCS and ARCT: Enhanced Submission Re: FDA-2026-N-4390 — AI-Enabled Optimization of Early-Phase Clinical Trials Regulatory Intent This framework directly addresses FDA's objective to improve efficiency, safety, and decision quality in early-phase clinical trials, specifically Phase 1 dose escalation and Phase 1-to-Phase 2 transition decisions. The RT-MSCCS (Real-Time Monitoring, Safety, and Control System) resolves translational bottlenecks in early drug development while maintaining rigorous human oversight and PI clinical autonomy. Re: A.1 — Phase 1 Dose Escalation as Primary Target Current dose escalation decisions rely on retrospective cohort review, introducing unnecessary delays between dose levels. RT-MSCCS addresses this through: real-time safety signal detection at each dose level; continuous Risk-Benefit Parity modeling; and automated flagging for go/no-go determinations at Phase 1-to-Phase 2 transition points. This enables investigators and FDA reviewers to assess dose-level safety data as it is generated. Re: B.2 — Decision Quality: Go/No-Go Support The RT-MSCCS hierarchical control logic — Adjustment → Warning → Hard Stop — maps directly onto dose escalation decisions: Adjustment: Minor deviations trigger real-time protocol modifications without interrupting the trial Warning: Emerging signals trigger mandatory PI review before the next dose level Hard Stop: Critical thresholds trigger immediate cessation with mandatory Clinical Override Workflow requiring verified PI intervention This replaces end-of-cohort retrospective review with continuous real-time assessment, directly reducing time from Phase 1 completion to Phase 2 initiation. Re: B.3 — Participant Safety: Alert Fatigue Even when a Hard Stop threshold is fixed, PI intervention capacity degrades over time due to repeated low-priority warnings. The threshold remains constant, but the human response capability erodes. RT-MSCCS addresses this through: tiered alert architecture separating low-signal Adjustments from high-priority Warnings; periodic Manual Ground-Truth Verification; and a hard-wired Fail-Safe protocol for immediate transition to manual control. PI response time and quality over trial duration should be a core evaluation metric. Re: B.4 — AI System Performance: Concept Drift Delta Detection & Concept Drift Monitoring tracks data distribution changes in real time, critical in Phase 1 trials where patient populations are small. Model drift should be evaluated not only at the system level but at the level of each individual trial. Re: B.5 — Trustworthiness: NIST AI RMF Alignment RT-MSCCS aligns with NIST AI Risk Management Framework principles: Valid and Reliable: Delta Detection ensures real-time statistical validity monitoring Safe: Hard Stop with mandatory PI override ensures patient safety is never compromised Explainable: XAI interface visualizes data features triggering each intervention Accountable: ADSGW maintains complete audit trails separating automated surveillance from human governance Privacy-protective: Protocols adhere to ALCOA+ and FHIR standards Fair: Manual Ground-Truth Verification includes demographic subgroup review The PI maintains ultimate authority. In any conflict between AI output and clinical judgment, human assessment prevails. Re: B.6 — Comparative Evaluation RT-MSCCS is designed for staged implementation: Stage 1: Observational pilot — monitoring only, establishing baseline data Stage 2: Limited integration with concurrent non-AI comparators Stage 3: Full-scale operation with continuous regulatory reporting Conclusion RT-MSCCS offers a concrete architectural model combining real-time dose escalation support, alert fatigue mitigation, and full NIST AI RMF alignment as a structural reference for FDA's pilot design and evaluation criteria development.